IL148034A0 - Methods of treating nuclear factor-kappa b mediated diseases and disorders - Google Patents

Methods of treating nuclear factor-kappa b mediated diseases and disorders

Info

Publication number
IL148034A0
IL148034A0 IL14803402A IL14803402A IL148034A0 IL 148034 A0 IL148034 A0 IL 148034A0 IL 14803402 A IL14803402 A IL 14803402A IL 14803402 A IL14803402 A IL 14803402A IL 148034 A0 IL148034 A0 IL 148034A0
Authority
IL
Israel
Prior art keywords
kappa
disorders
methods
mediated diseases
nuclear factor
Prior art date
Application number
IL14803402A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL148034A0 publication Critical patent/IL148034A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14803402A 2001-02-12 2002-02-06 Methods of treating nuclear factor-kappa b mediated diseases and disorders IL148034A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26820301P 2001-02-12 2001-02-12

Publications (1)

Publication Number Publication Date
IL148034A0 true IL148034A0 (en) 2002-09-12

Family

ID=23021923

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14803402A IL148034A0 (en) 2001-02-12 2002-02-06 Methods of treating nuclear factor-kappa b mediated diseases and disorders

Country Status (11)

Country Link
US (1) US20020183384A1 (xx)
EP (1) EP1236468A1 (xx)
JP (1) JP2002275062A (xx)
KR (1) KR20020067011A (xx)
CN (1) CN1370526A (xx)
AU (1) AU1539402A (xx)
CA (1) CA2369967A1 (xx)
HU (1) HUP0200493A3 (xx)
IL (1) IL148034A0 (xx)
NZ (1) NZ517021A (xx)
ZA (1) ZA200201161B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
GB0325192D0 (en) * 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
WO2005099686A1 (ja) * 2004-04-07 2005-10-27 Fujicco Co., Ltd. カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物
NZ587106A (en) * 2004-12-14 2012-03-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
JP2009539818A (ja) * 2006-06-08 2009-11-19 アストラゼネカ アクチボラグ ベンゾイミダゾールおよび糖尿病の処置のためのその使用
KR100842351B1 (ko) * 2007-01-04 2008-06-30 한국생명공학연구원 인돌 유도체를 유효성분으로 함유하는 암 예방 및 치료용약학적 조성물
AU2008290327A1 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
MX2011006672A (es) * 2008-12-19 2011-07-20 Astrazeneca Ab Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.
US9339524B2 (en) 2009-03-11 2016-05-17 Jellice Co., Ltd. Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food
BRPI1016109A2 (pt) 2009-06-19 2016-05-17 Astrazeneca Ab "composto, composição farmacêutica, e, processo para preparar um composto"
CN103040815B (zh) * 2011-10-13 2014-12-10 中国科学院上海药物研究所 一类2，4，6-三异丙基苯类化合物在制备治疗糖尿病的药物中的用途
MD3259253T2 (ro) * 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora
KR20180004242A (ko) * 2015-05-08 2018-01-10 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 알쯔하이머병의 치료를 위한 뉴런 저장소-작동된 칼슘 진입 경로의 활성화
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TWI789401B (zh) 2017-07-07 2023-01-11 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CU24615B1 (es) 2017-07-24 2022-07-08 Novartis Ag Compuestos para tratar afecciones asociadas con la actividad nlrp
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
UY37848A (es) * 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019034697A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RU2020110366A (ru) * 2017-08-15 2021-09-16 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
CN111315733A (zh) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759073A1 (en) * 2018-03-02 2021-01-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US5194588A (en) * 1985-01-22 1993-03-16 Ici Americas Inc. Aminoalcohol intermediates for peptide derivatives
US5245068A (en) * 1990-10-30 1993-09-14 Warner-Lambert Company Oxysulfonyl carbamates
US5254715A (en) * 1990-11-07 1993-10-19 Warner-Lambert Company Aminosulfonyl carbamates
US5214206A (en) * 1990-11-07 1993-05-25 Warner-Lambert Company Aminosulfonyl urea acat inhibitors
US5198466A (en) * 1990-11-09 1993-03-30 Warner-Lambert Company Oxysulfonyl urea acat inhibitors
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL122247A0 (en) * 1995-08-04 1998-04-05 Warner Lambert Co Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
GEP20001898B (en) * 1995-11-02 2000-01-05 Warner Lambert Co Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
US5948886A (en) * 1996-11-20 1999-09-07 Hoechst Marion Roussel, Inc. Acylated enol derivatives of α-ketoesters and α-ketoamides
AU2738897A (en) * 1996-05-17 1997-12-09 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
ATE242208T1 (de) * 1997-01-29 2003-06-15 Pfizer Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität
US6093744A (en) * 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
DK1145717T3 (da) * 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon

Also Published As

Publication number Publication date
HUP0200493A2 (en) 2002-10-28
HUP0200493A3 (en) 2003-04-28
HU0200493D0 (en) 2002-04-29
CN1370526A (zh) 2002-09-25
AU1539402A (en) 2002-08-15
ZA200201161B (en) 2003-08-11
NZ517021A (en) 2003-09-26
JP2002275062A (ja) 2002-09-25
EP1236468A1 (en) 2002-09-04
KR20020067011A (ko) 2002-08-21
CA2369967A1 (en) 2002-08-12
US20020183384A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
IL148034A0 (en) Methods of treating nuclear factor-kappa b mediated diseases and disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
IL157577A0 (en) Disposable underpants and method of providing the same
EP1455778A4 (en) METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
IL162184A0 (en) Treatment of asthma and respiratorydisease by means of electrical neuro-receptive waveforms
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
GB0329038D0 (en) Methods of well treatment
IL159313A0 (en) Methods for treatment of cognitive and menopausal disorders with d-threo-methylphenidate
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
IL145481A0 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
HUP0302233A3 (en) Methods of treating viral diseases with il-18 and il-18 combinations
PL366009A1 (en) Methods and compositions for the treatment of inflammatory diseases
HRP20020729A2 (en) Treatment of psoriasis
HRP20030384A2 (en) Treatment of anxiety disorders
IL140540A0 (en) Treatment of anxiety disorders
AU2003270540A8 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
PL351554A1 (en) Osanetant in the treatment of mood disorders
AU2003301346A8 (en) Method of treating neurological diseases and disorders
EP1458403A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND CLINICAL REMISSION OF PSORIASIS
IL161630A0 (en) Methods of treating endometreosis
IL142102A0 (en) Zinc-sensing receptor and methods of treatment of disorders associated herewith